NEW YORK (GenomeWeb) – Response Genetics said on Tuesday that it has been notified by the Nasdaq that it is not in compliance with a requirement to continue listing its shares on the exchange.

In a document filed with the US Securities and Exchange Commission, the Los Angeles-based molecular diagnostics company said it received a letter on June 20 from the Nasdaq staff stating that for the previous 30 consecutive business days, its shares had closed below the minimum $1 per share bid price for continued listing on the Nasdaq Capital Market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.